Spots Global Cancer Trial Database for A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
Official Title: A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma
Study ID: NCT04106219
Conditions
Study Description
Brief Summary: The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.
Detailed Description:
Eligibility
Minimum Age: 2 Years
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UCSF Medical Center at Mission Bay, San Francisco, California, United States
Children's Hospital Colorado, Aurora, Colorado, United States
University of Chicago - Comer Children's Hospital, Chicago, Illinois, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Texas Childrens Hospital, Houston, Texas, United States
Perth Children's Hospital, Perth, Western Australia, Australia
UZ Gent, Gent, Oost-Vlaanderen, Belgium
Centre Leon Berard, Lyon, Rhône-Alpes, France
Institut Curie, Paris CEDEX 05, , France
Universitätsklinikum Köln, Köln, , Germany
Istituto Nazionale dei Tumori, Milano, Lombardie, Italy
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona], Spain
Hospital Infantil Universitario Niño Jesús, Madrid, , Spain
Alder Hey Children's Hospital, Liverpool, , United Kingdom
Contact Details
Name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Affiliation: Eli Lilly and Company
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
